Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine/CPT-11 and Radiation for Locally Advanced Pancreatic Cancer
NCT00025168Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Nov 2001
- Primary completion
- Aug 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and irinotecan in pancreatic cancer (PC), sponsored by Wake Forest University Health Sciences. Primary endpoint: Time to Progression. Started Nov 2001; status: completed.
02
Drugs
gemcitabineirinotecan
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00025168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025168.